RE: 12p28 Jan 2021 12:35
Yes it was me.. I am sparticus!!
Although 12p was a little tongue in cheek there are, in my view, a number of risks in this company despite the very capable CEO. A lot of investors work on big assumptions and that is fine, but one also has to question the narrative of the past few months whereby the accelerated SP activity was down to some serious marketing which, in turn, paid off handsomely for a number of 'Institutional' ( I use that word cautiously) and retail early investors.
Orph have pivoted from orphan drug date, to testing (we heard no numbers on that) and to HCS model for covid at a cost of of several million if I recall for them to announce that covid was a small part of their business. So what is the big part is the logical question to underpin valuations.
The market driver for the SP was the rush to develop a vaccine and that (for now) has been achieved. Now you could all argue quite rightly that the current vaccines may fail in the end to cope with the virus mutations. If that is the case then there has to be proper consideration to the validity of the orph HCS model also in that scenario? So the investment case for me is binary; either the HCS stands up to new variants or becomes redundant or the vaccines being rolled out will be effective and the demand for HCS may fall.
Each HCS developed needs investment and time. If Cathal pays out dividends then where is that future capex coming from? Either the revenues fund growth in which case the CEO should be clear about it or it stays as contingency for future investment.
As for valuation, the balance sheet reflects 10-12m of non returnable revenue from work yet to be done does it not. Therefore future revenues are delayed until the work is actually done which won't be easy if the virus continually mutates and the company HCS plays catch up.
My point about the chicken is simple... the growth of the company is more than facilities for HCS, for CS companies it has to be investment in future capacity to develop support services outside of HCS and this, concerned me.
Lets be honest, institutions have been selling for three months or so and not once have I seen a post on here questioning anything other than them profit taking. The risk of being blinded here is high as if the CS business area is going to be in demand for the next decade why aren't II's sticking with it, or even investing more?
None of you know their motivations but are free to exercise free will and judgement. I sold out in the end as that was my decision and for the record I could be wrong. The reason for this post is simply to explain a logic. Whether to agree with it or not is not the point of it. Examining both sides it.
regards to all, even to Andino who drew me out skillfully. DJ